IsoRay Cultura de la Empresa

Mr. Alan Hoffmann, CPA, has been Independent Director of IsoRay, Inc. since January 13, 2016. In 2011, he served as CFO for an international manufacturing company, Kinematics Manufacturing, Inc. He holds his undergraduate accounting degree with honors from the University of Wisconsin-Milwaukee in 1985, he became a Certified Public Accountant in 1989.

Mr. Mark Austin, CPA has been Principal Accounting & Financial Officer and Controller of IsoRay, Inc. since July 24, 2017. Mr. Austin has over 8 years of broad accounting experience in roles of increasing responsibility at KPMG. He has extensive experience and training in all aspects of current accounting processes and procedures of public technology companies. He served as Senior Manager for Financial Statement and Internal Control Audits within the technology industry sector for KPMG, including a number of software and manufacturing companies and served as the Lead Manager of a global public company account for KPMG. He holds a BS in Accounting from Santa Clara University, Santa Clara, CA. He completed his CPA in 2010.

Mr. William Cavanagh, III, also known as Bill, has been the Chief Operating Officer of IsoRay, Inc. since March 3, 2016 and its Chief Scientific Officer since August 15, 2016. Mr. Cavanagh served as Vice President of Research and Development at IsoRay, Inc. since January 2010 until March 3, 2016. Mr. Cavanagh served as Interim Chief Executive Officer of IsoRay, Inc since January 7, 2016. Mr. Cavanagh serves as the Vice President of Research & Development of Isoray Medical Inc. He has an extensive background in bringing medical products to market for the treatment of cancer. He had engaged in the research and development of dendritic cell therapies for cancer and infectious diseases. He served as Chief Scientific Officer for Sangretech Biomedical for the past six years, where he oversaw the design and implementation of a novel cancer therapy. Mr. Cavanagh was responsible for study design, protocol development, establishing necessary technology, IRB approval, clinic and operating room procedures and the reporting of study results. Upon the licensing of the Sangretech technology to a U.S. development partner, Mr. Cavanagh oversaw the compilation and submittal of an Investigational New Drug (IND) application to the U.S. FDA. He began his extensive career in cancer treatment technologies in the early 1990s, when he helped lead research and development of a therapy involving the insertion of radioactive sources directly into the prostate for the treatment of prostate cancer (prostate brachytherapy). He has designed several cancer treatment-related studies, is listed as an author on 34 peer-reviewed publications and is the listed inventor on a U.S. patent application detailing a novel treatment for cancer. Mr. Cavanagh has also served as Director of the Haakon Ragde Foundation for Advanced Cancer Studies in Seattle, Washington, where he led the research foundation in the selection of viable research projects directed at treating advanced cancers. He holds B.A. in Chemistry from Lake Forest College.

Michael Krachon serves as the VP Sales and Marketing of Isoray Medical, Inc.. Michael started at Isoray Medical, Inc. in Mar of 2016. Michael currently resides in the Greater Atlanta Area.

Jonathan Hunt serves as the CFO of Isoray Medical, Inc.. Jonathan currently resides in the Richland/Kennewick/Pasco, Washington Area.

Fred Swindler serves as the Vice President of Isoray Medical, Inc.. Fred currently resides in the Knoxville, Tennessee Area.